

**Amendments to the Claims:**

Per 37 C.F.R. §1.121, the current status of all the claims in the present application is presented below, amended claims are notated to indicated changes made and the text of pending claims not being amended are presented clean. Amendments to the following are indicated by underlining what has been added and striking-through what has been deleted.

This listing of the claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. – 26. (Canceled)

27. (Currently amended) A method of detecting or diagnosing inflammatory bowel disease in a subject, comprising obtaining a biological sample from the subject and, ~~comprising screening the sample for~~ the polynucleotide sequence of SEQ ID NO:1 or a ~~fragment~~ portion thereof wherein the portion comprises at least 20 nucleotides as shown in SEQ ID NO: 1 and wherein an increase in the level of the polynucleotide or portion compared to control indicates inflammatory bowel disease

28. – 38. (Canceled)

39. (Previously presented) The method according to claim 27, wherein the inflammatory bowel disease is ulcerative colitis.

40. (Previously presented) The method according to claim 27, wherein the inflammatory bowel disease is Crohn's disease.

41. (New) The method according to claim 27, wherein the portion comprises at least 20 nucleotides selected from:

a) the nucleotide sequence of nucleotides 66 to 161 of SEQ ID NO:1;

- b) the complement of a);
- c) the nucleotide sequence of nucleotides 288 to 389 of SEQ ID NO:1;
- d) the complement of c);
- e) the nucleotide sequence of nucleotides 354 to 382 of SEQ ID NO:1;
- f) the complement of e;
- g) the nucleotide sequence of nucleotides 66 to 389 of SEQ ID NO:1; and
- f) the complement of g.

42. (New) The method according to claim 39, wherein the portion comprises at least 20 nucleotides selected from:

- a) the nucleotide sequence of nucleotides 66 to 161 of SEQ ID NO:1;
- b) the complement of a);
- c) the nucleotide sequence of nucleotides 288 to 389 of SEQ ID NO:1;
- d) the complement of c);
- e) the nucleotide sequence of nucleotides 354 to 382 of SEQ ID NO:1;
- f) the complement of e;
- g) the nucleotide sequence of nucleotides 66 to 389 of SEQ ID NO:1; and
- f) the complement of g.

43. (New) The method according to claim 40, wherein the portion comprises at least 20 nucleotides selected from:

- a) the nucleotide sequence of nucleotides 66 to 161 of SEQ ID NO:1;
- b) the complement of a);
- c) the nucleotide sequence of nucleotides 288 to 389 of SEQ ID NO:1;
- d) the complement of c);
- e) the nucleotide sequence of nucleotides 354 to 382 of SEQ ID NO:1;
- f) the complement of e;
- g) the nucleotide sequence of nucleotides 66 to 389 of SEQ ID NO:1; and
- f) the complement of g.